


KX1-004

Cat. No.:	HY-18237		
CAS No.:	518058-84-9		
Molecular Formula:	C ₁₆ H ₁₃ FN ₂ O ₂		
Molecular Weight:	284.29		
Target:	Src		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (351.75 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.5175 mL	17.5877 mL	35.1753 mL
	5 mM	0.7035 mL	3.5175 mL	7.0351 mL
	10 mM	0.3518 mL	1.7588 mL	3.5175 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

KX1-004 is a potent and non-ATP competitive Src-PTK inhibitor with an IC₅₀ of 40 μM. KX1-004 protects the cochlea from hazardous noise and prevents noise-induced hearing loss (NIHL)^{[1][2]}.

In Vivo

KX1-004 (30 μM) provides significant protection against noise-induced temporary threshold shift (TTS), permanent threshold shift (PTS) and outer hair cells (OHC) loss^[1].
KX1-004 (50 mg/kg) is effective against noise exposure^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Harris KC, et al. Prevention of noise-induced hearing loss with Src-PTK inhibitors. *Hear Res.* 2005 Oct;208(1-2):14-25.

[2]. Bielefeld EC, et al. A comparison of the protective effects of systemic administration of a pro-glutathione drug and a Src-PTK inhibitor against noise-induced hearing loss. *Noise Health.* 2005 Oct-Dec;7(29):24-30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA